Alimera announces multiple presentations highlighting iluvien® and yutiq® data at retina society annual congress

Atlanta, oct. 11, 2023 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (“alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for iluvien® (fluocinolone acetonide intravitreal implant) 0.19 mg and yutiq® (fluocinolone acetonide intravitreal implant) 0.18 mg will be featured in five presentations during the retina society's 56th annual scientific meeting being held in new york city from october 11-14, 2023.
ALIM Ratings Summary
ALIM Quant Ranking